Reacts with endothelial cell protein C receptor (EPCR), a 25 kDa, type I transmembrane glycoprotein, expressed on endothelial cells in arteries, veins and capillaries. EPCR is also referred to as CD201. It binds protein C and augments its activation. Reports indicate that EPCR is expressed on several malignant cell lines. Malignant cell lines that express EPCR also show significant levels of protein C activation and this activation could be inhibited by anti-EPCR antibody. This antibody is routinely tested by flow cytometric analysis. Other applications were tested during antibody development only or reported in the literature. Profile of anti-CD201 (RCR-252) reactivity on ECV304 cells analyzed by flow cytometry. Second step staining with Cat. No. 554016.
BD Pharmingen™ Purified Rat Anti-Human CD201 - Purified - Clone RCR-252 - Isotype Rat IgG1, κ - Reactivity Hu - 0.1 mg
Aufreinigung
The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C
Informationen zur Lagerung
Store undiluted at 4°C.
Biguzzi, Merati, Liaw, Bucciarelli, Oganesyan, Qu, Gu, Fetiveau, Esmon, Mannucci, Faioni: "A 23bp insertion in the endothelial protein C receptor (EPCR) gene impairs EPCR function." in: Thrombosis and haemostasis, Vol. 86, Issue 4, pp. 945-8, (2001) (PubMed).
Tsuneyoshi, Fukudome, Horiguchi, Ye, Matsuzaki, Toi, Suzuki, Kimoto: "Expression and anticoagulant function of the endothelial cell protein C receptor (EPCR) in cancer cell lines." in: Thrombosis and haemostasis, Vol. 85, Issue 2, pp. 356-61, (2001) (PubMed).